X0306 4 2016-08-16 0 0001377121 Protagonist Therapeutics, Inc PTGX 0001673237 Papanek Julie C/O PROTAGONIST THERAPEUTICS, INC. 521 COTTONWOOD DRIVE, SUITE 100 MILPITAS CA 95035 1 0 0 0 Common Stock 2016-08-16 4 C 0 1869922 A 1869922 I By Canaan X L.P. Common Stock 2016-08-16 4 P 0 583333 12.00 A 2453255 I By Canaan X L.P. Series C Preferred Stock 2016-08-16 4 C 0 27113877 D Common Stock 1869922 0 I By Canaan X L.P. The number of shares of common stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Preferred Stock converted into one share of common stock of the Issuer at the closing of the Issuer's initial public offering. Each share of the Issuer's Series C Preferred Stock, which had no expiration date, automatically converted into the Issuer's common stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering, for no additional consideration. These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The Reporting Person is a non-managing member of Canaan Partners X LLC, the general partner of the Canaan Fund. The Reporting Person does not have voting, investment or dispositive power over any of the shares directly held by the Canaan Fund and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Exhibit 24 - Power of Attorney (incorporated herein by reference to the Power of Attorney filed as Exhibit 24 to the Form 3 filed by the Reporting Person on August 10, 2016) Julie Papanek, By: /s/ Janine MacDonald, Attorney-in-Fact 2016-08-16